These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 28902084

  • 1. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy.
    Zubizarreta PA, Alfaro E, Guitter M, Sanchez La Rosa C, Galluzzo ML, Millán N, Fiandrino F, Felice MS.
    J Pediatr Hematol Oncol; 2017 Nov; 39(8):602-608. PubMed ID: 28902084
    [Abstract] [Full Text] [Related]

  • 2. Treatment of early clinically staged Hodgkin's disease with a combination of ABVD chemotherapy plus limited field radiotherapy.
    Karmiris TD, Grigoriou E, Tsantekidou M, Spanou E, Mihalakeas H, Baltadakis J, Apostolidis J, Pagoni M, Karakasis D, Bakiri M, Mitsouli C, Harhalakis N, Nikiforakis E.
    Leuk Lymphoma; 2003 Sep; 44(9):1523-8. PubMed ID: 14565654
    [Abstract] [Full Text] [Related]

  • 3. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study.
    Pavone V, Ricardi U, Luminari S, Gobbi P, Federico M, Baldini L, Iannitto E, Ucci G, Marcheselli L, Orsucci L, Angelucci E, Liberati M, Gavarotti P, Levis A, Intergruppo Italiano Linfomi (IIL).
    Ann Oncol; 2008 Apr; 19(4):763-8. PubMed ID: 18180244
    [Abstract] [Full Text] [Related]

  • 4. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ.
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [Abstract] [Full Text] [Related]

  • 5. Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
    Arakelyan N, Jais JP, Tomowiack C, Colombat P, Berthou C, Desablens B, Moles-Moreau MP, Gastinne T, Quittet P, Casassus P, Le Pourhiet-Le Mevel A, Ghandour C, Brière J, Colonna P, Andrieu JM.
    Leuk Lymphoma; 2013 Jan; 54(1):76-82. PubMed ID: 22680774
    [Abstract] [Full Text] [Related]

  • 6. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A, Ha FJ, Chong G, Grigg A, Mckendrick J, Schwarer AP, Doig R, Hamid A, Hawkes EA.
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [Abstract] [Full Text] [Related]

  • 7. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
    Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, Casagrande W, Pascutto C, Franchini P, Lazzarino M.
    Clin Cancer Res; 2006 Nov 01; 12(21):6487-93. PubMed ID: 17085663
    [Abstract] [Full Text] [Related]

  • 8. Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.
    Kamran SC, Jacene HA, Chen YH, Mauch PM, Ng AK.
    Leuk Lymphoma; 2018 Jun 01; 59(6):1384-1390. PubMed ID: 28937297
    [Abstract] [Full Text] [Related]

  • 9. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi.
    N Engl J Med; 2011 Jul 21; 365(3):203-12. PubMed ID: 21774708
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M, Itoh K, Ishizawa K, Kobayashi Y, Tobinai K, Kinoshita T, Hirano M, Ueda R, Shibata T, Nakamura S, Tsukasaki K, Hotta T, Shimoyama M, Morishima Y, Lymphoma Study Group (LSG) of Japan Clinical Oncology Group (JCOG).
    Leuk Lymphoma; 2013 Jan 21; 54(1):46-52. PubMed ID: 22712838
    [Abstract] [Full Text] [Related]

  • 11. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
    Iannitto E, Minardi V, Gobbi PG, Calvaruso G, Tripodo C, Marcheselli L, Luminari S, Merli F, Baldini L, Stelitano C, Callea V, Petrini M, Angrilli F, Quarta G, Vallisa D, Molica S, Liardo E, Polimeno G, Brugiatelli M, Federico M.
    Clin Lymphoma Myeloma; 2009 Apr 21; 9(2):138-44. PubMed ID: 19406724
    [Abstract] [Full Text] [Related]

  • 12. Limited-stage Hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy.
    Bartlett NL.
    Am Soc Clin Oncol Educ Book; 2013 Apr 21; ():374-80. PubMed ID: 23714551
    [Abstract] [Full Text] [Related]

  • 13. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A.
    J Clin Oncol; 2017 Jun 20; 35(18):1999-2007. PubMed ID: 28418763
    [Abstract] [Full Text] [Related]

  • 14. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
    Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE, NCIC Clinical Trials Group, Eastern Cooperative Oncology Group.
    N Engl J Med; 2012 Feb 02; 366(5):399-408. PubMed ID: 22149921
    [Abstract] [Full Text] [Related]

  • 15. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
    Kedmi M, Apel A, Davidson T, Levi I, Dann EJ, Polliack A, Ben-Bassat I, Nagler A, Avigdor A.
    Acta Haematol; 2016 Feb 02; 135(3):156-61. PubMed ID: 26588173
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
    Hamed RH, Anter AH, Awad IA.
    Hematol Oncol Stem Cell Ther; 2012 Feb 02; 5(1):36-41. PubMed ID: 22446609
    [Abstract] [Full Text] [Related]

  • 17. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.
    J Clin Oncol; 2010 Sep 20; 28(27):4199-206. PubMed ID: 20713848
    [Abstract] [Full Text] [Related]

  • 18. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology.
    Oberlin O, Leverger G, Pacquement H, Raquin MA, Chompret A, Habrand JL, Terrier-Lacombe MJ, Bey P, Bertrand Y, Rubie H.
    J Clin Oncol; 1992 Oct 20; 10(10):1602-8. PubMed ID: 1383434
    [Abstract] [Full Text] [Related]

  • 19. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
    Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, Pinto A.
    Br J Haematol; 2014 Jul 20; 166(1):118-29. PubMed ID: 24673727
    [Abstract] [Full Text] [Related]

  • 20. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
    Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V.
    N Engl J Med; 2010 Aug 12; 363(7):640-52. PubMed ID: 20818855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.